Citigroup Inc Aligos Therapeutics, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.89 - $28.0 $425 - $13,384	-478 Reduced 84.9%	85 $0
Q3 2022 Nov 10, 2022	SELL	$1.06 - $27.5 $1,111 - $28,847	-1,049 Reduced 65.07%	563 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.04 - $2.14 $5,550 - $11,421	-5,337 Reduced 76.8%	1,612 $2,000
Q1 2022 May 12, 2022	SELL	$2.08 - $12.2 $1,185 - $6,954	-570 Reduced 7.58%	6,949 $15,000
Q4 2021 Feb 10, 2022	BUY	$11.48 - $17.69 $50,477 - $77,782	4,397 Added 140.84%	7,519 $89,000
Q3 2021 Nov 10, 2021	BUY	$14.57 - $17.72 $45,487 - $55,321	3,122 New	3,122 $48,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.66B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.